Sol-Gel Technologies Ltd. (SLGL)
NASDAQ: SLGL · IEX Real-Time Price · USD
0.940
+0.018 (2.01%)
Apr 23, 2024, 12:18 PM EDT - Market open

Company Description

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel.

The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.

It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products.

It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Sol-Gel Technologies Ltd.
Sol-Gel Technologies logo
Country Israel
Founded 1997
IPO Date Jan 23, 2018
Industry Biotechnology
Sector Healthcare
Employees 36
CEO Dr. Alon Seri-Levy

Contact Details

Address:
7 Golda Meir St., Weizmann Science Park
Ness Ziona, L3 7403648
Israel
Phone 97289313433
Website sol-gel.com

Stock Details

Ticker Symbol SLGL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001684693
CUSIP Number M8694L103
ISIN Number IL0011417206
SIC Code 2834

Key Executives

Name Position
Dr. Alon Seri-Levy Co-Founder, Chief Executive Officer and Director
Gilad Mamlok Chief Financial Officer
Dr. Itzik Yosef Chief Operating Officer
Moshe Arkin Executive Chairman of the Board
Prof. David Avnir Co-Founder
Tamar Fishman Jutkowitz Vice President and General Counsel
Dr. Karine Neimann Vice President of Projects and Planning and Chief Chemist

Latest SEC Filings

Date Type Title
Apr 8, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Apr 4, 2024 424B3 Prospectus
Apr 1, 2024 EFFECT Notice of Effectiveness
Apr 1, 2024 6-K Report of foreign issuer
Mar 20, 2024 POS AM Post-Effective amendments for registration statement
Mar 13, 2024 20-F Annual and transition report of foreign private issuers
Mar 13, 2024 6-K Report of foreign issuer
Mar 6, 2024 6-K Report of foreign issuer
Feb 29, 2024 6-K Report of foreign issuer
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals